Abstract
Bone remodelling and bone loss are controlled by a balance between the tumour necrosis factor family molecule osteoprotegerin ligand (OPGL) and its decoy receptor osteoprotegerin (OPG)1,2,3. In addition, OPGL regulates lymph node organogenesis, lymphocyte development and interactions between T cells and dendritic cells in the immune system3,4,5. The OPGL receptor, RANK, is expressed on chondrocytes, osteoclast precursors and mature osteoclasts4,6. OPGL expression in T cells is induced by antigen receptor engagement7, which suggests that activated T cells may influence bone metabolism through OPGL and RANK. Here we report that activated T cells can directly trigger osteoclastogenesis through OPGL. Systemic activation of T cells in vivo leads to an OPGL-mediated increase in osteoclastogenesis and bone loss. In a T-cell-dependent model of rat adjuvant arthritis characterized by severe joint inflammation, bone and cartilage destruction and crippling, blocking of OPGL through osteoprotegerin treatment at the onset of disease prevents bone and cartilage destruction but not inflammation. These results show that both systemic and local T-cell activation can lead to OPGL production and subsequent bone loss, and they provide a novel paradigm for T cells as regulators of bone physiology.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Simonet,W. S. et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309–319 (1997).
Lacey,D. L. et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165–176 (1998).
Kong,Y. Y. et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315–323 (1999).
Anderson,D. M. et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell fucntion. Nature 390, 175–179 (1997).
Wong,B. r. et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J. Exp. Med. 186, 2075–2080 (1997).
Hsu,H. et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl Acad. Sci. USA 96, 3540–3545 (1999).
Wong,B. R. et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272, 25190–25194 (1997).
Felix,R., Hofstetter,W. & Cecchini,M. G. Recent developments in the understanding of the pathophysiology of osteopetrosis. Eur. J. Endocrinol. 134, 143–156 (1996).
Roodman,G. D. Advances in bone biology: the osteoclast. Endocr. Rev. 17, 308–332 (1996).
Roodman,G. D. Paget's disease and osteoclast biology. Bone 19, 209–212 (1996).
Coleman,R. E., Smith,P. & Rubens,R. D. Clinical course and prognostic factors following bone recurrence from breast cancer. Br. J. Cancer 77, 336–340 (1998).
Stellon,A. J., Davies,A., Compston,J. & Williams,R. Bone loss in autoimmune chronic active hepatitis on maintenance corticosteroid therapy. Gastroenterology 89, 1078–1083 (1985).
Oliveri,M. B., Mautalen,C. A., Rodriguez Fuchs,C. A. & Romanelli,M. C. Vertebral compression fractures at the onset of acute lymphoblastic leukemia in a child. Henry Ford Hosp. Med. J. 39, 45–48 (1991).
Piepkorn,B. et al. Bone mineral density and bone metabolism in diabetes mellitus. Horm. Metab. Res. 29, 584–591 (1997).
Feldmann,M., Brennan,F. M. & Maini,R. N. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14, 397–440 (1996).
Kotake,S. et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 103, 1345–1352 (1999).
Josien,R., Wong,B. R., Li,H. L., Steinman,R. M. & Choi,Y. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J. Immunol. 162, 2562–2568 (1999).
Waterhouse,P. et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270, 985–988 (1995).
Mombaerts,P. et al. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68, 869–877 (1992).
Bendele,A. et al. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data. Arthritis Rheum. 42, 498–506 (1999).
Panayi,G. S., Lanchbury,J. S. & Kingsley,G. H. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum. 35, 729–735 (1992).
Muller-Ladner,U., Gay,R. E. & Gay,S. Molecular biology of cartilage and bone destruction. Curr. Opin. Rheumatol. 10, 212–219 (1998).
Conway,J. G. et al. Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor. J. Exp. Med. 182, 449–457 (1995).
Faust,J. et al. Osteoclast markers accumulate on cells developing from human peripheral blood mononuclear precursors. J. Cell. Biochem. 72, 67–80 (1999).
Acknowledgements
We thank E. C. Keystone for providing patient samples and C. Dunstan for critical comments. Technical assistance was provided by Y. Cheng, E. Julian, C. Burgh, A. Shahinian and D. Duryea. We are grateful to M. E. Saunders for scientific editing and A. Hessel, A. Oliveira dos Santos, K. Bachmaier, T. Sasaki and all other members of the laboratory for comments.
Author information
Authors and Affiliations
Supplementary information
Supplementary Information
Supplementary Information
Rights and permissions
About this article
Cite this article
Kong, YY., Feige, U., Sarosi, I. et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402, 304–309 (1999). https://doi.org/10.1038/46303
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/46303
This article is cited by
-
Comparative study of the synovial levels of RANKL and OPG in rheumatoid arthritis, spondyloarthritis and osteoarthritis
Advances in Rheumatology (2023)
-
Osteonecrosis of the jaw induced by immune checkpoint inhibitors: an urgent need for attention
Journal of Translational Medicine (2023)
-
Effect of JAK inhibitors on the three forms of bone damage in autoimmune arthritis: joint erosion, periarticular osteopenia, and systemic bone loss
Inflammation and Regeneration (2023)
-
Osteoimmunology in Periodontitis and Orthodontic Tooth Movement
Current Osteoporosis Reports (2023)
-
Identification of 12 hub genes associated to the pathogenesis of osteoporosis based on microarray and single-cell RNA sequencing data
Functional & Integrative Genomics (2023)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.